TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05714202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAR-200
Description: TAR-200 will be administered intravesically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAR-200
Description: TAR-200 will be administered intravesically.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetrelimab
Description: Cetrelimab will be administered.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG Vesiculture
Description: BCG will be administered intravesically.
Study: NCT06567314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivonescimab
Description: Given by PO
Study: NCT05588323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naldemedine
Description: Administered as an oral tablet (0.2 mg dose level only), or oral suspension (all dose levels)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naldemedine
Description: Administered as an oral tablet (0.2 mg dose level only), or oral suspension (all dose levels)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naldemedine
Description: Administered as an oral tablet (0.2 mg dose level only), or oral suspension (all dose levels)
Study: NCT05497531

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ctDNA Blood Collection
Description: Blood collection to be obtained from peripheral vein and cancer draining vein during biopsy
Study: NCT06513104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0519-0130
Description: NNC0519-0130 will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel + Ethinylestradiol
Description: Levonorgestrel + Ethinylestradiol will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Paracetamol will be administered orally.
Study: NCT06106893

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 Universal CAR-γδ T Cells
Description: Intravenous infusion of CD19 Universal CAR-γδ T Cells
Study: NCT05859191

Intervention type: BIOLOGICAL
Intervention: Blood sample
Description: Three extra tubes of blood will be taken at each consultation or inpatient visit when routine blood samples are taken as part of lupus monitoring.
Study: NCT05711615

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and tissue sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peposertib
Description: Given PO
Study: NCT05107960

Intervention type: DRUG
Intervention: Azilsartan (TAK-536)
Description: Azilsartan Tablets, Azilsartan Granules
Study: NCT04773158

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support
Description: The intervention clinic sites will be provided access to a Clinical Decision Support System (CDSS) that incorporates the Rome IV criteria for evidence-based care recommendations for functional gastrointestinal disorders (FGIDs)
Study: NCT03335228

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eclipse Easy Spin for PRP
Description: Autologous platelet rich plasma is prepared from subject's blood with the Eclipse Easy Spin centrifuge and injected into affected areas.
Study: NCT04269239

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Healthy Habits
Description: Participants in this group will be coached during four hour-long sessions on topics such as physical activity, nutrition, pain coping skills, bladder health, diabetes, heart health, eyes/vision, hearing, and doctor-patient communication.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sleep Habits
Description: Participants in this group will be coached during four hour-long sessions on topics such as sleep education, sleep restriction, stimulus control, cognitive restructuring, sleep hygiene education, and relapse prevention.
Study: NCT06363825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: camrelizumab
Description: TAE: 3-15ml iodized oil;~HAIC: Indurating arterial catheter, oxaliplatin 85mg/m\^2 D1, arterial infusion, lasting 1-2 hours (d1), LV 400mg/m\^2, arterial infusion, lasting 2-3 hours (d1), 5-Fu 400mg/m\^2, arterial infusion, lasting 3 hours (d1), and fluorouracil 2400 mg/m\^2 for 24-48h;~camrelizumab: 200mg, ivgtt, 30 min (not less than 20 min, not more than 60 min) every 3 weeks (21 days);~apatinib mesylate: 250mg, once a day, taken orally (the time of daily administration should be as much as possible), with warm water.Stop for 3 days before next cycle intervention.~Camrelizumab was given intravenously 1 day before TAE+HAIC treatment for each cycle, TAE+HAIC treatment was given on the second day, and oral apatinib was started after discharge.
Study: NCT06038435

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Orientation Approach
Description: Cognitive training will be given for the selected occupation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ayres Sensory Integration Therapy
Description: Sensory integration therapy will be applied.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ayres Sensory Integration Therapy
Description: Sensory integration therapy will be applied.
Study: NCT06006832

Intervention type: DRUG
Intervention: Steroid Drug
Description: Maintaining low-dose oral steroids

Intervention type: OTHER
Intervention: Withdraw all immunosuppresants
Description: Withdraw all immunosuppresants
Study: NCT06304285

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Description: Acupuncture was performed according to the corresponding acupoint of the patient

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture treatment
Description: The needle only touches the patient's skin and does not penetrate the skin
Study: NCT06280274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 500mg oral once daily for 7 days, increased to 1000mg (500mg twice daily) for another 7 days, taken in morning and evening with meals, for a total of 14 days of treatment prior to surgery. Continue dose on day of surgery and up to post operative day 2, or until time of discharge, whichever happens first.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study: NCT06325839

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HypnoBirthing training and oxytocin massage group
Description: HypnoBirthing training and oxytocin massage were applied for a total of 12 hours for 4 weeks with the experimental group.
Study: NCT05286255

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Mesenchymal Stromal Cells
Description: Intravenous MSCs 1.2-1.5 x 10\^6 cells/kg on Days 1 and 3 after study enrollment
Study: NCT06191809

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Controlled Ovarian Stimulation Protocol
Description: Ovarian Stimulation Process:~* Stimulate ovaries with FSH \& hMG (150-375 IU) starting day 2-3 of menstruation.~* Monitor response with ultrasound \& hormones (E2, LH, P4).~* GnRH-ant arm: Prevent LH surge with Cetrorelix (0.25mg) starting day 5.~* PPOS arm: Suppress LH with Dydrogesterone (10mg x 3/day) from day 1.~* Trigger ovulation when ≥2 follicles \>17mm (Triptorelin, hCG, or rhCG).~* Oocyte retrieval 36-38 hours later (\>10mm follicles aspirated).~Embryo Culture \& Monitoring:~* Fertilize with ICSI.~* Culture \& evaluate embryos (43-45 hours, day 3/5).~* Freeze all embryos.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Controlled Ovarian Stimulation Protocol
Description: Ovarian Stimulation Process:~* Stimulate ovaries with FSH \& hMG (150-375 IU) starting day 2-3 of menstruation.~* Monitor response with ultrasound \& hormones (E2, LH, P4).~* GnRH-ant arm: Prevent LH surge with Cetrorelix (0.25mg) starting day 5.~* PPOS arm: Suppress LH with Dydrogesterone (10mg x 3/day) from day 1.~* Trigger ovulation when ≥2 follicles \>17mm (Triptorelin, hCG, or rhCG).~* Oocyte retrieval 36-38 hours later (\>10mm follicles aspirated).~Embryo Culture \& Monitoring:~* Fertilize with ICSI.~* Culture \& evaluate embryos (43-45 hours, day 3/5).~* Freeze all embryos.
Study: NCT05971914

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autogenous tooth derived particulate graft and a novel split thickness papilla curtain flap
Description: Extracted deciduous teeth were prepared immediately after removal according to the manufacturer's instructions with the Bonmaker® device. Ready to use autogenous tooth bone graft (ATB) was mixed with fibrin glue in 3D planned and printed plastic cuvettes to obtain a sticky graft closely matching the shape and extent of the bony defect. The preshaped sticky ATB graft was inserted and compacted in the cleft defect. Subsequently, the tension-free split thickness flap was repositioned by shifting all buccal surgical papillae mesially to the adjacent or the second adjacent interproximal space, depending on the horizontal extent of the cleft.
Study: NCT06462950

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Do men and women differ in their reactions to the experimental conditions.
Description: Do men and women differ in their reactions to the experimental conditions.
Study: NCT05375123

Intervention type: DEVICE
Intervention: Ultrasound image acquisition
Description: Echocardiography: left ventricular systolic function of all participants were measured by tissue motion tracking of mitral annular displacement using PHILIPS.~Time points for heart image acquisition in pregnant women: As per the Guidelines for Pre-pregnancy and Pregnancy Health Care (2018) formulated by the Obstetrics Group of the Gynecology Branch of the Chinese Medical Association, a total of six echocardiographic examinations will be performed in the first trimester (11-14 weeks of gestation), the second trimester (20-24 weeks of gestation), the third trimester (29-32 weeks of gestation), prenatal term (37-41 weeks of gestation), 6 weeks and 3-6 months after delivery.~Time points for fetal heart image acquisition: Fetal heart images will be collected in the second trimester (20 to 24 weeks of gestation).
Study: NCT06434792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bronpass Tab.
Description: Twice daily for 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice daily for 12 weeks
Study: NCT05724264

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Low-dose CT of the Chest (LDCT) + Sampling for Biomarker Assays
Description: LDCT scan results will be reported based on the Lung-RADS classification. Participants will be stratified into various Lung-RADS groups based on the CT appearance and size of nodules. An alphanumeric Lung-RADS score will be assigned to each subject which will guide the downstream management of screened participants.~All subjects will be required to donate drawn blood samples (up to 30 ml) at every LDCT visit during screening surveillance, and at every LDCT/CT scan and/or biopsy visits during clinical surveillance for blood-based biomarker assays development and characterization. Subjects may also be asked to provide a sample of urine, saliva and breath for biomarker discovery.
Study: NCT05677048

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Free genetic testing and counseling group
Description: Option to access no-cost telegenetic counseling and genetic testing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Free genetic testing and counseling group
Description: Option to access no-cost telegenetic counseling and genetic testing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Free genetic testing and counseling group
Description: Option to access no-cost telegenetic counseling and genetic testing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IGNITE-TX Group
Description: Access online educational materials through the IGNITE-TX platform and receive assistance from a family genetic navigator

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IGNITE-TX Group
Description: Access online educational materials through the IGNITE-TX platform and receive assistance from a family genetic navigator

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IGNITE-TX Group
Description: Access online educational materials through the IGNITE-TX platform and receive assistance from a family genetic navigator

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IGNITE-TX and free genetic testing and counseling group
Description: Option to access no-cost telegenetic counseling and genetic testing, access to online educational materials through the IGNITE-TX platform, and assistance from a family genetic navigator

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IGNITE-TX and free genetic testing and counseling group
Description: Option to access no-cost telegenetic counseling and genetic testing, access to online educational materials through the IGNITE-TX platform, and assistance from a family genetic navigator

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IGNITE-TX and free genetic testing and counseling group
Description: Option to access no-cost telegenetic counseling and genetic testing, access to online educational materials through the IGNITE-TX platform, and assistance from a family genetic navigator
Study: NCT05543681

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IGC-AD1-Active
Description: A non-sterile solution for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IGC-AD1-Placebo
Description: A non-sterile solution for oral administration similar in color and texture to the Active.
Study: NCT06501092

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Point Mini
Description: Patient is fit with the Point Mini finger prosthetic system, which consists of 1-4 ratcheting mechanical digits and mounting brackets
Study: NCT05958342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Gluconate
Description: 1 gram calcium gluconate provided via intravenous or intraosseous access over approximately 2-5 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: 4 unit vasopressin bolus followed by vasopressin infusion at 0.04 U/min for eight hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline placebo
Description: saline placebo volume matched to prehospital or in hospital phase

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline placebo
Description: saline placebo volume matched to prehospital or in hospital phase
Study: NCT05329363

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PEPITS Programme
Description: The programme has three main phases:~Phase I: Introduction phase (Session 1) Phase II: Pathology and care work phase (Sessions 2 - 3 - 4) Phase III: Recovery and stepping stone phase (Sessions 5 - 6 - 7) The programme provides information, keys and new skills to the patient through 3 phases focusing on pathology and recovery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Patients will receive the same psychiatric care as the experimental group except of the PEPITS programme.
Study: NCT05436262

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-time fMRI with neurofeedback of motor imagery
Description: Participants undergo a real-time fMRI scan during which they are provided feedback regarding the accuracy of their motor imagery performance.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-time fMRI with neurofeedback of motor imagery
Description: Participants undergo a real-time fMRI scan during which they are provided feedback regarding the accuracy of their motor imagery performance.
Study: NCT06336083

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound
Description: Participants will receive doppler ultrasound of the carotid arteries, and no other interventions studied
Study: NCT05884476

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment-as-usual
Description: Veterans in the TAU-only control condition will remain engaged in their normal standard of mental health care throughout their participation in this study. Veterans in the TAU condition will have access to and receive referrals for any of the following services normally afforded to patients at this VA hospital: VA Office of Connected Care web-based training programs and mobile mental health applications; primary care appointments; PCMHI consultation; outpatient mental health individual and group therapies; psychiatry appointments; inpatient hospitalization in the event of a suicidal crisis during study participation; and post-discharge mental health follow-up appointments following inpatient hospitalization for medical or mental health reasons.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Re-Evaluating Suicidal Thoughts
Description: REST is a brief, computerized intervention designed to mitigate psychological inflexibility associated with the experience of suicidal ideation. Most individuals complete the intervention in under one hour. REST provides psychoeducation to correct common misconceptions about suicidal ideation and help Veterans de-catastrophize the occurrence and meaning of these thoughts. This includes information about the prevalence of suicidal ideation among Veterans, a conceptualization of suicidal ideation as a response to stress, normalizing emotional reactions to suicidal ideation, and framing suicidal ideation as thoughts and conjectures as opposed to truth and reality. These components were chosen to directly address emotional distress related to suicidal thoughts, which is central to the construct of psychological inflexibility. Veterans randomized to receive REST will have access to and be encouraged to utilize any and all of these options described in the TAU-only condition.
Study: NCT06143696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qingxin Zishen decoction
Description: Oral administration, 1 dose daily, twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Femoston
Description: Oral administration, 1 pill each time, once a day
Study: NCT06342180

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum uric acid level
Description: An amount of 2-3 ml of blood sample will be collected from the patients after 8-12 hours of fasting and will be kept frozen at -70 degrees to calculate the serum UA level.

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum uric acid level
Description: An amount of 2-3 ml of blood sample will be collected from the patients after 8-12 hours of fasting and will be kept frozen at -70 degrees to calculate the serum UA level.

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum uric acid level
Description: An amount of 2-3 ml of blood sample will be collected from the patients after 8-12 hours of fasting and will be kept frozen at -70 degrees to calculate the serum UA level.

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum uric acid level
Description: An amount of 2-3 ml of blood sample will be collected from the patients after 8-12 hours of fasting and will be kept frozen at -70 degrees to calculate the serum UA level.

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum uric acid level
Description: An amount of 2-3 ml of blood sample will be collected from the patients after 8-12 hours of fasting and will be kept frozen at -70 degrees to calculate the serum UA level.
Study: NCT05069402

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immunonutrition
Description: diet with immunonutrients

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High-protein
Description: Oral nutrition with high-protein content

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard ONS
Description: Oral nutrition with standard ingredients
Study: NCT03809364

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: START Together
Description: Behavioral intervention using a cognitive behavioral couple therapy (CBCT) framework designed to improve the couple's communication and problem-solving behavior.
Study: NCT05416905

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STN-DBS
Description: The patients will be treated with deep brain electrode placement of STN target under local and general anesthesia. Switching the system on: the stimulator will be switched on 3 weeks after surgery to allow time for the brain edema and stun effect to wear off. Postoperative medication: The subject taking medication in the past will continue the medication. If the subject with no medication before, will be required not to take medication related to dystonia.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GPi-DBS
Description: The patients will be treated with deep brain electrode implantation of GPi target under local and general anesthesia. Except that the surgical target was GPi, the operation process, stimulator switch-on time, and postoperative medication were the same as those in the STN-DBS group.
Study: NCT05448898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine CU Xiu Tang
Description: Oral Traditional Chinese Medicine CU Xiu Tang once a day and repeat and deliberate sniffing of a set of odorants for 20 seconds each at least twice a day for at least 3 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olfactory Training
Description: repeat and deliberate sniffing of a set of odorants for 20 seconds each at least twice a day for at least 3 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olfactory Training
Description: repeat and deliberate sniffing of a set of odorants for 20 seconds each at least twice a day for at least 3 months
Study: NCT05699421

Intervention type: OTHER
Intervention: screening programme
Description: CMV screening during the first trimester of pregnancy and neonatal
Study: NCT04309825

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transgastrostomal endoscopy
Description: Placement the endoscope through the g-tube port and not through the mouth of a patient undergoing an upper gi endoscopy
Study: NCT04949958

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Based Manual (Supervised)
Description: Exercise Based Manual for Pre Diabetic subjects will consist of two components; Exercise, Exercise and Education. The exercise will be supervised while other component will be home based.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Based Manual (Home Based)
Description: Exercise Based Manual for Pre Diabetic subjects will consist of two components; Exercise and Education. All two components will be home based.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: General advice to be active